Burden of COVID-19 in immunocompromised patients in Germany: a retrospective, observational Study on Health Insurance Data from 2021 to 2022.

ABSTRACT:

Purpose

Patients with COVID-19 and immunocompromising conditions are threatened with higher morbidity, mortality and a greater economic burden than immunocompetent persons due to an inadequate immune response to infection and vaccination. Health and economic COVID-19 outcomes in 2021 and 2022, a period during which vaccines became available gradually, were investigated.

Methods

This retrospective observational study was based on statutory health insurance (SHI) claims data of approximately 2.7 million insurees each of 2021 and 2022, extrapolated to the overall German SHI population. An immunocompromised group was defined via several risk factors. COVID-19-related outcomes were compared to a group without risk factors (immunocompetent group).

Results

In both years, COV

SUBMITTER: Weinmann-Menke J 

PROVIDER: S-EPMC12460495 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature